Zucara Therapeutics Inc, a Canada-based diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycaemia (low blood glucose levels), announced on Wednesday that it has dosed the first patients in its Phase 1b trial of ZT-01.
The study is to enrol around 25 Type 1 diabetes patients who will undergo a hypoglycaemic clamp procedure including administration of either ZT-01 or placebo.
The main aim of the study is to assess the effect of the product on glucagon levels. Other study objectives include further assessment of the safety and tolerability of the product and assessment of symptoms and other hormones related to hypoglycaemia. Top line results are likely to be revealed in the first quarter of 2022. The study is to be conducted at LMC Manna Research, providing phase one to four clinical trial services with a specialised focus on diabetes and general endocrine disorders. The company has already completed a single and multiple ascending dose Phase one trial, in which the product was safe and well-tolerated.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults